#United States #San Diego #Class Action #Securities Fraud #UroGen Pharma

Class Action Lawsuit for UroGen Pharma Investors

Investors who purchased or acquired securities of UroGen Pharma Ltd. (NASDAQ: URGN) between July 27, 2023, and May 15, 2025, are facing a pivotal moment as they may lead a class action lawsuit against the company. The allegations highlight potential violations of the Securities Exchange Act of 1934, implicating UroGen, alongside some current and former executives, in significant misstatements affecting investors.

Background of the Case

Robbins Geller Rudman & Dowd LLP, a prominent law firm, is spearheading this class action. The case is officially filed under the name Cockrell v. UroGen Pharma Ltd. and is set forth in the District of New Jersey (Case No. 25-cv-06088). Investors who endured substantial losses due to alleged misleading information provided during the class period have until July 28, 2025, to step forward as lead plaintiffs.

The allegations center on UroGen’s lead product, UGN-102, an intravesical solution targeting low-grade intermediate risk non-muscle invasive bladder cancer. Critically, issues surrounding the clinical trials and the product's efficacy are at the heart of this class action lawsuit.

Allegations Against UroGen Pharma

The claim suggests that during the given time frame, UroGen made several false or misleading statements regarding its clinical study, ENVISION, for UGN-102. The flaws highlighted are:

• - Lack of Control in Clinical Design: The study did not include a concurrent control arm, which is essential to demonstrate substantial evidence of effectiveness.
• - Potential Risks Not Disclosed: It was alleged that the FDA's warnings regarding the study's inadequacy for a new drug application (NDA) were ignored by UroGen, leading to an anticipated rejection of the NDA regarding UGN-102.
• - Stock Price Volatility: Following the criticism from the FDA detailing the study design flaws, UroGen’s stock plummeted nearly 26% on May 16, 2025. A further decline of nearly 45% followed after the Oncologic Drugs Advisory Committee voted against approving UGN-102 due to unfavorable benefit-risk assessments on May 21, 2025.

The Class Action Mechanics

Under the Private Securities Litigation Reform Act of 1995, any investor affected during this class period can apply to act as a lead plaintiff. The lead plaintiff represents the interests of all class members, directing the overall course of the lawsuit. This individual can choose their legal representation to pursue this matter further. However, it should be noted that participating as a lead plaintiff does not affect the potential for recovery any investor might claim.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is well-known for their endeavor in representing investors in matters around securities fraud and shareholder litigation. They have gained significant accolades, ranking #1 for several years in securing monetary recoveries for investors, showcasing their effectiveness in this domain. Last year, their efforts brought in over $2.5 billion in securities-related class actions, making them a formidable player in shareholder litigation.

Investors who wish to learn more about the class action or seek representation can reach out to Robbins Geller through their official communication channels. The impacts of this lawsuit may be pivotal for countless investors who have seen their investments dwindle due to alleged corporate mismanagement and misinformation.

For those interested in participating, detailed information about how to submit claims and engage with this lawsuit is available on the Robbins Geller website. It is crucial for affected investors to act promptly to secure their standing in this potentially lucrative class action process.